I ntroduction

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90145/1/phco.20.18.347S.34608.pd

Evolution and Pathophysiology of Chronic Systolic Heart Failure

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90037/1/phco.20.18.349S.34605.pd

Carvedilol: Therapeutic Application and Practice Guidelines

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90381/1/j.1875-9114.1998.tb03895.x.pd

Food: An Unrecognized Source of Loop Diuretic Resistance

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90131/1/phco.24.6.630.34736.pd

Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension

Azilsartan–chlorthalidone fixed combination is a new drug in the management of hypertension. Azilsartan has been shown to have greater blood pressure-lowering effects than other angiotensin-receptor blockers (ARBs), and the debate regarding the superiority of chlorthalidone over hydrochlorothiazide has been ongoing for years. The combination is unique because it is the first to partner an ARB with this, possibly more effective, diuretic. This review will address trials involving both components of this drug, as well as phase III trials involving the fixed-combination product. The article will also discuss the benefit of combination therapy in the treatment of hypertension

Implementing and evaluating virtual patient cases within a team‐based learning pedagogy in a therapeutics course sequence

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149331/1/jac51053.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/149331/2/jac51053_am.pd

Comparison of adrenergic agonists for the treatment of ventricular fibrillation and pulseless electrical activity

The primary role of epinephrine for the treatment of ventricular fibrillation (VF) and pulseless electrical activity (PEA) is to increase blood flow to the myocardium and central nervous system and ultimately improve survival. However, despite the administration of epinephrine, survival following VF or PEA is low. In an attempt to improve outcome from VF and PEA, alternative adrenergic agonists (methoxamine, phenylephrine, norepinephrine) which have different pharmacological properties than epinephrine have been evaluated. In order to determine the role of alternative adrenergic agonists for the treatment of VF and PEA this paper will compare the pharmacological properties and pharmacodynamic effects of these drugs to epinephrine. Specifically, receptor physiology along with the effects of adrenergic agonists on coronary perfusion pressure, survival, myocardial oxygen demand, and cerebral blood flow will be discussed.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/31146/1/0000043.pd

Diurnal Variation in Plasma Norepinephrine in Patients with Heart Failure

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90311/1/phco.19.11.984.31571.pd

A Web Application for Self-Monitoring Improves Symptoms in Chronic Systolic Heart Failure

Objective: The objective of this study was to determine if a Web application that promoted mindfulness of the progress of the chronic disease through self-monitoring improved quality of life in heart failure. Materials and Methods: This was a prospective single-center single-group study. Participants were instructed how to use the Web application and to perform self-monitoring daily for 12 weeks. A comprehensive physical exam, assessment of New York Heart Association (NYHA) class, the Minnesota Living with Heart Failure Questionnaire (MLHFQ), and an evaluation of self-management were performed in person at baseline and at 12 weeks. Results: Participants consisted of older (mean, 59 years), predominantly female (63%) adults with NYHA class II or III symptoms. NYHA classification (preintervention versus postintervention, 2.5±0.13 versus 2.0±0.13; p=0.0032) and MLHFQ score (55.7±4.6 versus 42.6±5.1, respectively; p=0.0078) improved over 12 weeks of self-monitoring. A trend toward improvement was also demonstrated in weight (preintervention versus postintervention, 209±9.6 pounds versus 207±9.4 pounds; by paired t test, p=0.389), number of times exercised per week (1.29±0.5 versus 2.5±0.6, respectively; p=0.3), and walk distance (572±147 yards versus 845±187 yards, respectively; p=0.119). Jugular venous distention (preintervention versus postintervention, 8.1±0.6?cm versus 6.7±0.3?cm; p=0.083) and peripheral edema (29.2% versus 16.7%, respectively; p=0.375) decreased after 12 weeks of self-monitoring via the Web application. Conclusions: A Web application for self-monitoring heart failure over 12 weeks improved both NYHA classification and MLHFQ score. The trend in improved physical activity and physical exam support these outcomes. The number of patients reporting a sodium-restricted diet increased over the 12 weeks, which may have led to the positive findings.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/140281/1/tmj.2014.0095.pd

Hematologic and Chemical Changes Observed during and after Cardiac Arrest in a Canine Model—A Pilot Study

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90335/1/phco.21.15.1187.33899.pd